查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552698

非肌肉浸润性膀胱癌市场 - 全球产业分析、规模、份额、成长、趋势和预测，2024-2034 年

Non-muscle Invasive Bladder Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 165 Pages | 商品交期: 2-10个工作天内

价格

非肌肉浸润性膀胱癌市场 - 报告范围

TMR 关于全球非肌肉层浸润性膀胱癌市场的报告研究了过去以及当前的成长趋势和机会，以获得2024 年至2034 年预测期内市场指标的宝贵见解。膀胱癌市场的收入2018-2034年期间非肌肉层浸润性膀胱癌市场，考虑2024年为基准年，2034年为预测年。报告中也提供了2024年至2034年全球非肌肉层浸润性膀胱癌市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解非肌肉层浸润性膀胱癌市场。

市场概况
2023年市场价值 26 亿美元
2034 年市场价值 211 亿美元
复合年增长率 21.4%

该报告深入研究了全球非肌肉层浸润性膀胱癌市场的竞争格局。全球非肌肉层浸润性膀胱癌市场的主要参与者已经确定，并且每一位参与者都已根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球非肌肉浸润性膀胱癌市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：市场

第 4 章：市场概述

  • 介绍
  • 概述
  • 市场动态
  • 2020-2034年市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：依治疗类型

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依治疗类型，2020-2034
    • 免疫治疗
    • 化疗
    • 标靶治疗
  • 市场吸引力分析：按治疗类型

第 7 章：全球市场分析与预测：按癌症类型

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按癌症类型，2020-2034
    • 低度膀胱癌
    • 高级别膀胱癌
  • 市场吸引力分析：按癌症类型

第 8 章：全球市场分析与预测：按配销通路

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按配销通路，2020-2034
    • 医院药房
    • 零售药局
    • 网路药局
  • 市场吸引力分析：按配销通路

第 9 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020-2034
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 10 章：北美市场分析与预测

第 11 章：欧洲市场分析与预测

第 12 章：亚太市场分析与预测

第 13 章：拉丁美洲市场分析与预测

第 14 章：中东和非洲市场分析与预测

第 15 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司分类（2023）
  • 公司简介
    • Liminal BioSciences Inc.
    • TARIS Biomedical LLC
    • Merck & Co., Inc.
    • Herantis Pharma Oyj
    • Viventia Bio Inc.
    • Telormedix SA
    • Ferring BV
    • Altor BioScience Corporation
    • Novartis AG
    • Pfizer Inc.
    • GSK plc
    • Sanofi SA
    • Eli Lilly and Company
    • AstraZeneca
Product Code: TMRGL86334

Non-muscle Invasive Bladder Cancer Market - Scope of Report

TMR's report on the global non-muscle invasive bladder cancer market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global non-muscle invasive bladder cancer market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global non-muscle invasive bladder cancer market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the non-muscle invasive bladder cancer market.

Market Snapshot
Market Value in 2023US$ 2.6 Bn
Market Value in 2034US$ 21.1 Bn
CAGR21.4%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global non-muscle invasive bladder cancer market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global non-muscle invasive bladder cancer market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global non-muscle invasive bladder cancer market.

The report delves into the competitive landscape of the global non-muscle invasive bladder cancer market. Key players operating in the global non-muscle invasive bladder cancer market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global non-muscle invasive bladder cancer market profiled in this report.

Key Questions Answered in Global non-muscle invasive bladder cancer Market Report:

  • What is the sales/revenue generated by non-muscle invasive bladder cancer across all regions during the forecast period?
  • What are the opportunities in the global non-muscle invasive bladder cancer market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Non-muscle Invasive Bladder Cancer Market - Research Objectives and Research Approach

The comprehensive report on the global non-muscle invasive bladder cancer market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global non-muscle invasive bladder cancer market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global non-muscle invasive bladder cancer market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Non-muscle Invasive Bladder Cancer Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 6.3.1. Immunotherapy
    • 6.3.2. Chemotherapy
    • 6.3.3. Targeted Therapy
  • 6.4. Market Attractiveness Analysis, by Treatment Type

7. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Cancer Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Cancer Type, 2020-2034
    • 7.3.1. Low Grade Bladder Cancer
    • 7.3.2. High Grade Bladder Cancer
  • 7.4. Market Attractiveness Analysis, by Cancer Type

8. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Non-muscle Invasive Bladder Cancer Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 10.3.1. Immunotherapy
    • 10.3.2. Chemotherapy
    • 10.3.3. Targeted Therapy
  • 10.4. Market Value Forecast, by Cancer Type, 2020-2034
    • 10.4.1. Low Grade Bladder Cancer
    • 10.4.2. High Grade Bladder Cancer
  • 10.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Treatment Type
    • 10.7.2. By Cancer Type
    • 10.7.3. By Distribution Channel
    • 10.7.4. By Country

11. Europe Non-muscle Invasive Bladder Cancer Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 11.3.1. Immunotherapy
    • 11.3.2. Chemotherapy
    • 11.3.3. Targeted Therapy
  • 11.4. Market Value Forecast, by Cancer Type, 2020-2034
    • 11.4.1. Low Grade Bladder Cancer
    • 11.4.2. High Grade Bladder Cancer
  • 11.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Treatment Type
    • 11.7.2. By Cancer Type
    • 11.7.3. By Distribution Channel
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Non-muscle Invasive Bladder Cancer Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 12.3.1. Immunotherapy
    • 12.3.2. Chemotherapy
    • 12.3.3. Targeted Therapy
  • 12.4. Market Value Forecast, by Cancer Type, 2020-2034
    • 12.4.1. Low Grade Bladder Cancer
    • 12.4.2. High Grade Bladder Cancer
  • 12.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Treatment Type
    • 12.7.2. By Cancer Type
    • 12.7.3. By Distribution Channel
    • 12.7.4. By Country/Sub-region

13. Latin America Non-muscle Invasive Bladder Cancer Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 13.3.1. Immunotherapy
    • 13.3.2. Chemotherapy
    • 13.3.3. Targeted Therapy
  • 13.4. Market Value Forecast, by Cancer Type, 2020-2034
    • 13.4.1. Low Grade Bladder Cancer
    • 13.4.2. High Grade Bladder Cancer
  • 13.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Retail Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Treatment Type
    • 13.7.2. By Cancer Type
    • 13.7.3. By Distribution Channel
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Non-muscle Invasive Bladder Cancer Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 14.3.1. Immunotherapy
    • 14.3.2. Chemotherapy
    • 14.3.3. Targeted Therapy
  • 14.4. Market Value Forecast, by Cancer Type, 2020-2034
    • 14.4.1. Low Grade Bladder Cancer
    • 14.4.2. High Grade Bladder Cancer
  • 14.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Treatment Type
    • 14.7.2. By Cancer Type
    • 14.7.3. By Distribution Channel
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Liminal BioSciences Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. TARIS Biomedical LLC
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Merck & Co., Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Herantis Pharma Oyj
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Viventia Bio Inc.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Telormedix SA
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Ferring B.V.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Altor BioScience Corporation
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Novartis AG
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Pfizer Inc.
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. GSK plc
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Sanofi S.A.
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview
    • 15.3.13. Eli Lilly and Company
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Product Portfolio
      • 15.3.13.3. SWOT Analysis
      • 15.3.13.4. Financial Overview
      • 15.3.13.5. Strategic Overview
    • 15.3.14. AstraZeneca
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Product Portfolio
      • 15.3.14.3. SWOT Analysis
      • 15.3.14.4. Financial Overview
      • 15.3.14.5. Strategic Overview

List of Tables

  • Table 1: Global Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 2: Global Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 3: Global Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 4: Global Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 5: North America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 6: North America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 7: North America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 8: North America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 9: Europe Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 11: Europe Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 12: Europe Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 13: Asia Pacific Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 15: Asia Pacific Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 16: Asia Pacific Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 17: Latin America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 19: Latin America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 20: Latin America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 23: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 24: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 1: Global Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
  • Figure 2: Global Non-muscle Invasive Bladder Cancer Market Revenue (US$ Bn), by Treatment Type, 2023
  • Figure 3: Global Non-muscle Invasive Bladder Cancer Market Value Share, by Treatment Type, 2023
  • Figure 4: Global Non-muscle Invasive Bladder Cancer Market Revenue (US$ Bn), by Cancer Type, 2023
  • Figure 5: Global Non-muscle Invasive Bladder Cancer Market Value Share, by Cancer Type, 2023
  • Figure 6: Global Non-muscle Invasive Bladder Cancer Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 7: Global Non-muscle Invasive Bladder Cancer Market Value Share, by Distribution Channel, 2023
  • Figure 8: Global Non-muscle Invasive Bladder Cancer Market Value Share, by Region, 2023
  • Figure 9: Global Non-muscle Invasive Bladder Cancer Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 10: Global Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 11: Global Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
  • Figure 13: Global Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 14: Global Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 15: Global Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 16: Global Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Non-muscle Invasive Bladder Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 21: North America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 22: North America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
  • Figure 23: North America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 24: North America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: North America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 26: North America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 27: Europe Non-muscle Invasive Bladder Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Europe Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Europe Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 30: Europe Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 31: Europe Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
  • Figure 32: Europe Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 33: Europe Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Europe Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 35: Europe Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 36: Asia Pacific Non-muscle Invasive Bladder Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Asia Pacific Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Asia Pacific Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 39: Asia Pacific Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 40: Asia Pacific Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
  • Figure 41: Asia Pacific Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 42: Asia Pacific Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Asia Pacific Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 44: Asia Pacific Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 45: Latin America Non-muscle Invasive Bladder Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Latin America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Latin America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Latin America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 49: Latin America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
  • Figure 50: Latin America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Latin America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Latin America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 53: Latin America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 54: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 55: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 56: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 58: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
  • Figure 59: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 60: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 61: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 62: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034